Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience

Autor: Richard D. Kreutzer, Jeffrey M. Gambel, Max Grogl, Robert A. Gasser, Philip E. Coyne, Jeffrey S. Beard, Joan E. Jackson, Alan J. Magill, Naomi E. Aronson, Paul M. Benson, Steven C. Johnson, Timothy P. Endy, Glenn Wortmann, Charles N. Oster, John D. Tally
Rok vydání: 1998
Předmět:
Zdroj: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 27(6)
ISSN: 1058-4838
Popis: The efficacy and toxicity of sodium stibogluconate (SSG) at a dosage of 20 mg/(kg.d) for either 20 days (for cutaneous disease) or 28 days (for visceral, mucosal, or viscerotropic disease) in the treatment of leishmaniasis is reported. Ninety-six U.S. Department of Defense health care beneficiaries with parasitologically confirmed leishmaniasis were prospectively followed for 1 year. One patient was infected with human immunodeficiency virus; otherwise, comorbidity was absent. Clinical cure occurred in 91% of 83 cases of cutaneous disease and 93% of 13 cases of visceral/viscerotropic disease. Adverse effects were common and necessitated interruption of treatment in 28% of cases, but they were generally reversible. These included arthralgias and myalgias (58%), pancreatitis (97%), transaminitis (67%), headache (22%), hematologic suppression (44%), and rash (9%). No subsequent mucosal leishmaniasis was identified, and there were no deaths attributable to SSG or leishmaniasis.
Databáze: OpenAIRE